Researchers at the Icahn School of Medicine at Mount Sinai have unveiled critical new insights into how APOE4—the most significant genetic risk factor for Alzheimer’s disease—actively dismantles the brain’s vascular health and disrupts cellular waste disposal. Published in two high-impact studies in Cell and Cell Stem Cell, the findings challenge the long-standing belief that vascular damage in Alzheimer’s is merely a byproduct of the disease, suggesting instead that it is a direct, potentially reversible, driver of neurodegeneration.
For the millions of older adults living with Alzheimer’s in the United States, these discoveries represent a significant pivot in understanding. While the link between APOE4 and cognitive decline has been established for decades, the precise mechanisms behind the brain’s physical degradation have remained elusive. By utilizing a cutting-edge human brain tissue platform known as "miBrains," the research team has successfully mapped the pathways of destruction and identified potential therapeutic targets that could one day preserve brain function in those at the highest genetic risk.
Mapping the Vascular Destruction of APOE4
The vascular system of the brain is a complex, delicate network essential for maintaining cognitive health. Scientists have long observed that as Alzheimer’s progresses, the blood vessels in the brain deteriorate, particularly in carriers of the APOE4 gene. Historically, this vascular collapse was often viewed as a secondary symptom—a consequence of the disease rather than a primary trigger. The study published in Cell on September 24 overturns this perspective, positioning vascular dysfunction as a biologically active process.
To reach this conclusion, the Mount Sinai team synthesized existing datasets to construct a single-cell transcriptomic atlas of the human brain’s vascular system. This comprehensive map allowed researchers to visualize how individual cells behave in the presence of the APOE4 gene. Their findings revealed that the gene specifically targets pericytes, the cells responsible for stabilizing small blood vessels and maintaining the integrity of the blood-brain barrier.
In the presence of APOE4, these pericytes undergo a dangerous metamorphosis, transforming into myofibroblast-like cells. Instead of acting as structural supports, these transformed cells begin to produce scar tissue. This process, known as vascular fibrosis, creates a restrictive environment that impairs blood flow and fosters the accumulation of amyloid-beta proteins—the hallmark plaques associated with Alzheimer’s disease—around the blood vessels.
Crucially, the research team discovered that this trajectory is not inevitable. By inhibiting TGF-β signaling—a pathway involved in cell communication and tissue remodeling—the researchers were able to prevent the pericytes from transforming. In experiments conducted on aged mice carrying the APOE4 gene, this intervention successfully restored pericyte coverage, reduced fibrosis, and cleared amyloid buildup.
"Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible," said Joel W. Blanchard, PhD, the corresponding author of the study and an Associate Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai. "These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation."
Braxton R. Schuldt, an MD/PhD candidate in Neuroscience and the study’s first author, emphasized the clinical implications. "We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain’s vessels. Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease."
Human miBrains as a Gateway to Discovery
The success of these studies was heavily dependent on the development of "miBrains," a three-dimensional human brain tissue model derived from induced pluripotent stem cells. Unlike traditional two-dimensional cell cultures, miBrains replicate the complex architecture of the human brain, including the intricate network of blood vessels and a diverse array of cell types, such as neurons, glial cells, and myelin-producing cells.
By combining the miBrains platform with preclinical models, postmortem human brain tissue analysis, and transcriptomic data, the researchers created a multi-layered approach that allowed them to observe the disease process in real-time. This methodology enabled the team to pinpoint the exact events that occur before severe, irreversible vascular damage takes hold, providing a window of opportunity for therapeutic intervention that has previously been impossible to capture.
APOE4 and the Breakdown of Cellular Cleanup
In a parallel study published in Cell Stem Cell, the researchers utilized the miBrain platform to investigate another insidious effect of APOE4: its role in the accumulation of toxic proteins like alpha-synuclein, which is deeply implicated in Parkinson’s disease and Lewy body dementia.
Investigating protein buildup within a living human brain is exceptionally difficult, as the process occurs over years or even decades. The miBrain system, however, allowed the team to witness these dynamics in a controlled laboratory environment. They observed that in miBrains carrying the APOE4 gene, astrocytes—the support cells that act as the brain’s housekeepers—began to accumulate excess cholesterol.
This cholesterol buildup severely hampered the astrocytes’ lysosomal waste-disposal system. Under normal conditions, lysosomes act as the cell’s internal recycling centers, breaking down waste products like alpha-synuclein. When this system fails due to APOE4-driven cholesterol accumulation, the toxic proteins are not cleared away. Instead, they accumulate and eventually spill over into nearby neurons, forming the harmful deposits that lead to neurodegeneration.
This finding identifies cholesterol metabolism and lysosomal function as vital, previously under-explored therapeutic targets. By addressing the underlying metabolic disruption within the astrocytes, researchers may be able to restore the brain’s natural ability to clear toxic proteins, potentially slowing or halting the progression of multiple neurodegenerative conditions.
A New Horizon for Personalized Medicine
The utility of the miBrain platform extends beyond general discovery; it offers a scalable and reproducible framework for personalized medicine. A major advantage of this technology is the ability to cryopreserve the tissue for future studies, allowing researchers to build a library of brain models with predefined genetic profiles.
"A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," explained Louise Mesentier-Louro, PhD, Assistant Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai and first author of the Cell Stem Cell study. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."
The team is now working to develop miBrains derived from individual patients. This personalized approach could eventually allow clinicians to investigate why neurodegenerative diseases manifest differently in different patients and predict how a specific individual might respond to a particular drug.
"At Mount Sinai we are creating and cryopreserving miBrains from patients," Dr. Blanchard added. "This will enable personalized studies into how neurodegenerative disease develops and how individuals may respond to therapies. By enabling potential therapies to be tested earlier and more efficiently, the miBrain platform could help bridge the gap between laboratory discoveries and treatments for a broad range of disorders."
The research was supported by a wide array of prestigious institutions and organizations, including the National Aeronautics and Space Administration, the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Michael J. Fox Foundation for Parkinson’s Research, the CureAlz Fund, and the SWT Foundation. As these studies move forward, the hope is that these laboratory-grown models will serve as the engine for the next generation of life-saving Alzheimer’s treatments, turning the tide on a disease that has long seemed insurmountable.
